Malignant Hyperthermia

A summary of malignant hyperthermia treatment waits for patients undergoing cardiac surgery to lie on the operating table. The anesthesiologist enters the operating room and injects general anesthetic into the patient's blood. The patient seemed normal until after a few minutes, and the patient suddenly experienced a rise in body temperature, resulting in high fever, muscle stiffness and increased heart rate. The anesthesiologist was disturbed, ran out of the operating room and warned the operator of the warning symptoms.

In this case, a 35-year-old female patient developed malignant hyperthermia during surgery. Malignant hyperthermia is a rare primary drug that causes metabolic motor hyperresponsiveness in skeletal muscle. . The age, the type of anesthesia, the ambient temperature, and the level of palliative medication and concurrently applied stress play an important role in triggering malignant hyperthermia. . Primarily, a powerful inhalation anesthetic such as succinylcholine and depolarizing muscle relaxant are the main triggers of all triggers. Malignant hyperthermia may occur at any time during surgery, especially after introduction of anesthesia and early postoperative. In addition, there is a trend of recurrent episodes of malignant hyperthermia

Fever is not the earliest symptom of malignant hyperthermia, even though hypermetabolism of skeletal muscle causes hyperthermia and rhabdomyolysis. The earliest signs and symptoms of malignant hyperthermia are the concentration of carbon dioxide in the final breath (EtCO 2), tachycardia and muscle strength (especially when succinylcholine is administered). . In addition, the slow sign of malignant hyperthermia is the rise in body temperature. Other signs and symptoms are unstable blood pressure, shortness of breath, hyperkalemia, arrhythmia.